Predictors of Mortality and Morbidity in Patients with Chronic Heart Failure
Overview
Authors
Affiliations
Aims: We aimed to develop prognostic models for patients with chronic heart failure (CHF).
Methods And Results: We evaluated data from 7599 patients in the CHARM programme with CHF with and without left ventricular systolic dysfunction. Multi-variable Cox regression models were developed using baseline candidate variables to predict all-cause mortality (n=1831 deaths) and the composite of cardiovascular (CV) death and heart failure (HF) hospitalization (n=2460 patients with events). Final models included 21 predictor variables for CV death/HF hospitalization and for death. The three most powerful predictors were older age (beginning >60 years), diabetes, and lower left ventricular ejection fraction (EF) (beginning <45%). Other independent predictors that increased risk included higher NYHA class, cardiomegaly, prior HF hospitalization, male sex, lower body mass index, and lower diastolic blood pressure. The model accurately stratified actual 2-year mortality from 2.5 to 44% for the lowest to highest deciles of predicted risk.
Conclusion: In a large contemporary CHF population, including patients with preserved and decreased left ventricular systolic function, routine clinical variables can discriminate risk regardless of EF. Diabetes was found to be a surprisingly strong independent predictor. These models can stratify risk and help define how patient characteristics relate to clinical course.
McDowell K, Docherty K, Campbell R, Henderson A, Jhund P, Claggett B JAMA Cardiol. 2025; .
PMID: 40042880 PMC: 11883611. DOI: 10.1001/jamacardio.2025.0025.
Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment.
Fabiani I, Chianca M, Cipolla C, Cardinale D Nat Rev Cardiol. 2025; .
PMID: 39875555 DOI: 10.1038/s41569-025-01126-1.
Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy-Challenges and Prospectives.
Khattab E, Kyriakou M, Leonidou E, Sokratous S, Mouzarou A, Myrianthefs M Pharmaceuticals (Basel). 2025; 18(1).
PMID: 39861195 PMC: 11768626. DOI: 10.3390/ph18010134.
Hurst M, Zema C, Krause T, Sandler B, Lemmer T, Noon K BMJ Open. 2025; 14(12):e080142.
PMID: 39806583 PMC: 11667302. DOI: 10.1136/bmjopen-2023-080142.
Therapeutic Consequences and Prognostic Impact of Multimorbidity in Heart Failure: Time to Act.
Banfi-Bacsardi F, Kazay A, Gergely T, Forrai Z, Fuzesi T, Hanuska L J Clin Med. 2025; 14(1.
PMID: 39797222 PMC: 11722306. DOI: 10.3390/jcm14010139.